trending Market Intelligence /marketintelligence/en/news-insights/trending/VXOTBx0LCQ5uGdxTjrhzdw2 content esgSubNav
In This List

Biogen Q4'16 earnings slashed by license agreement

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Biogen Q4'16 earnings slashed by license agreement

Biogen Inc. reported a 22% year-over-year decrease in its fourth-quarter 2016 GAAP income.

The result, $649.2 million, or $2.99 per share, compares to $831.6 million, or $3.77 per share, in the 2015 fourth quarter and reflects a license agreement that resulted in a $455 million pre-tax charge during the closing months of 2016.

Biogen recently secured the rights to use Forward Pharma A/S' method for treating multiple sclerosis for $1.25 billion in cash. Biogen will make the payment and possibly up to 10% or 20% in royalties on the sale of Tecfidera, which uses Forward's patent protected method for multiple sclerosis.

The $455 million charge represents the portion of the payment attributable to the sales of Tecfidera during the April 2014 to Dec. 31, 2016, period.

Excluding the charge, Biogen recorded $1.09 billion, or $5.04 per share, in non-GAAP net income for the 2016 fourth quarter. This would compare to $995 million, or $4.50 per share, for the corresponding quarter of 2015.

The result beats the S&P Capital IQ consensus normalized EPS estimate of $4.96.

Biogen recorded $2.87 billion in revenues during the fourth quarter of 2016, bringing the year's total up by 6% to $11.45 billion when compared to 2015.

The company's full-year 2016 GAAP net income was also up to $3.70 billion, or $16.93 per share, from $3.55 billion, or $15.34 per share, in 2015.

Biogen recorded $4.42 billion, or $20.22 per share, in full-year 2016 non-GAAP income, which would compare to the $3.93 billion, or $17.01 per share, recorded in 2015.

Full-year non-GAAP income also beats the S&P Capital IQ consensus normalized EPS estimate of $20.17.

Biogen will target between $18 and $18.80 in GAAP and $20.45 and $21.25 in non-GAAP income during 2017.